The cumulative survival rates for 6 months were 66.7% and 100% in the group with serum PGRN levels ≥200 ng/ml (n =12), including two patients treated with HSCT, and the group with serum PGRN levels <200 ng/ml (n =29) in DM with ILD, respectively (Figure 4). This evidence concerns the gene GRN and dermatomyositis.